Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity

• Published in: Proceedings of the National Academy of Sciences Vol. 121; no. 35; p. e2320189121
• Main Authors: Mukohara, Fumiaki, Iwata, Kazuma, Ishino, Takamasa, Inozume, Takashi, Nagasaki, Joji, Ueda, Youki, Suzawa, Ken, Ueno, Toshihide, Ikeda, Hideki, Kawase, Katsushige, Saeki, Yuka, Kawashima, Shusuke, Yamashita, Kazuo, Kawahara, Yu, Nakamura, Yasuhiro, Honobe-Tabuchi, Akiko, Watanabe, Hiroko, Dansako, Hiromichi, Kawamura, Tatsuyoshi, Suzuki, Yutaka, Honda, Hiroaki, Mano, Hiroyuki, Toyooka, Shinichi, Kawazu, Masahito, Togashi, Yosuke
• Format: Journal Article
• Language: English
• Published: United States Proceedings of the National Academy of Sciences 27.08.2024; National Academy of Sciences
• Subjects: Animals; Anticancer properties; Antitumor activity; Biological Sciences; Biomarkers; Cancer; CD3 antigen; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Clonal deletion; Cloning; Female; Frameshift mutation; Gene deletion; Gene sequencing; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunity; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - immunology; Melanoma; Melanoma - genetics; Melanoma - immunology; Mice; Mice, Knockout; Mutation; PD-1 protein; Phenotypes; Therapeutic targets; Tumor Necrosis Factor alpha-Induced Protein 3 - genetics; Tumor-infiltrating lymphocytes; Whole genome sequencing; tumor-infiltrating lymphocytes; somatic mutation; T cell; cancer immunology

Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8 + T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic...